NIAID Site Search

Dr. Fauci testimony slides: The Role of the National Institute of Allergy and Infectious Diseases in Research Addressing Zika Virus May 2016

Last Reviewed: May 12, 2016

GVIRF 2021 Presentations Introduction to GVIRF (B. Fenton Hall, NIAID) Keynote Speakers Vaccinology in the context of pandemic preparedness: The COVID-19 experience (Anthony Fauci, NIAID) The lessons of COVID-19 for vaccine development (Bill Gates, BMGF) Innovating from research to impact at scale: the role of the Gavi Alliance (Anuradha Gupta, Gavi) Research for equity (Soumya Swaminathan, WHO)

Last Reviewed: April 21, 2022

Senior Leadership for NIAID's Vaccine Research Center (VRC)

Last Reviewed: February 25, 2025

Today, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to the Janssen Pharmaceuticals Companies of Johnson & Johnson for its single-shot COVID-19 vaccine, called Ad.26.COV2S or JNJ-78436725. The Janssen vaccine is a recombinant vector vaccine that uses a human adenovirus to express the spike protein found on the surface of the SARS-CoV-2 virus that causes COVID-19

Published: February 27, 2021

The Role of NIAID in Research Addressing Zika Virus: Hearing of the Senate Health, Education, Labor, and Pensions Committee February 24, 2016

Last Reviewed: August 6, 2019

NIH Opening Statement Senate LHHS FY 2019 Hearing: Prepared statement of Lawrence A. Tabak, D.D.S., PH.D., Principal Deputy Director, Office of the Director

Last Reviewed: August 16, 2018

How would you summarize what you currently do at NIAID? I am currently senior investigator and chief of the HIV Immunovirology Section in the Laboratory of Immunoregulation at NIAID. I direct and work with a small, but highly productive group of researchers and clinicians who 1) study the role of viral reservoirs in the pathogenesis of HIV disease; 2) examine host and viral factors that contribute

Last Reviewed: April 6, 2023

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002